PSMA-Targeted Polyplex dsRNA and Checkpoint Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies face challenges in effectively activating the immune system against cancer cells, particularly in prostate cancer, due to obstacles in reaching tumor-associated antigens and insufficient immune response activation.
Innovation Solution
A combinatorial immunotherapeutic approach using a polyplex comprising double-stranded RNA and a polymeric conjugate with polyethyleneimine, polyethylene glycol, and targeting moieties capable of binding to prostate-specific membrane antigen (PSMA), combined with immune checkpoint modulators to enhance immune system activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target tumor-associated antigens, then specific immune response is activated, but efficacy is limited due to insufficient activation of anti-tumor immune response and inhibition by tumor-induced immune reaction
Solution Approach 1:
The patent combines multiple therapeutic components into a single composition: checkpoint blockade antibodies (to inhibit immune suppression), cytokines (to activate immune response), and adjuvants (to enhance antigen presentation). This merging of functions overcomes the limitation of single-antibody therapies by simultaneously addressing both immune activation and inhibition pathways
Solution Approach 2:
The invention creates a composite immunotherapeutic formulation containing antibodies, cytokines, adjuvants, and potentially other agents in specific combinations. This composite approach allows synergistic interactions between components, where the whole therapeutic effect exceeds the sum of individual agent effects, thereby improving overall efficacy
2Reliability
If checkpoint blockade antibodies are used to inhibit immune checkpoints, then T cell activity is enhanced, but tumor cells may develop resistance through alternative immune resistance mechanisms
Solution Approach 1:
The patent employs multiple immune modulating agents that preemptively counteract potential resistance mechanisms. By including cytokines that activate alternative immune pathways and adjuvants that enhance antigen presentation through multiple mechanisms, the therapy prevents tumors from developing resistance through single-pathway adaptation
Solution Approach 2:
The invention dynamically modulates multiple immune parameters simultaneously through different agent classes: checkpoint blockade alters T cell receptor signaling parameters, cytokines modify cytokine milieu parameters, and adjuvants change antigen presentation parameters. This multi-parameter modulation makes it difficult for tumors to develop resistance
3Reliability
If vaccine-based therapy is used to induce antigen-specific T cell responses, then targeted immune response is generated, but clinical outcomes are disappointing due to insufficient immune response activation
Solution Approach 1:
The patent incorporates adjuvants that perform preliminary action by priming the immune system before antigen exposure. These adjuvants pre-activate immune cells and enhance antigen-presenting cell function, creating a primed state that amplifies the subsequent antigen-specific response to vaccine components
Solution Approach 2:
The invention uses cytokines as intermediary molecules that bridge the gap between antigen presentation and T cell activation. These cytokines mediate the interaction between vaccine components and immune cells, enhancing the amplitude of the immune response by providing necessary co-stimulatory signals
4Reliability
If combination therapy with multiple immunotherapeutic agents is used, then immune system activation is enhanced, but treatment complexity and potential toxicity increase
Solution Approach 1:
The patent merges multiple immunotherapeutic agents into a single combined composition that can be administered as one treatment regimen. This merging reduces the complexity of administering multiple separate therapies while maintaining the synergistic benefits of combination therapy
Solution Approach 2:
The invention creates a multi-functional therapeutic composition where single agents perform multiple functions: checkpoint blockade antibodies simultaneously block multiple checkpoint pathways, cytokines provide both direct immune activation and indirect enhancement of antigen presentation, and adjuvants offer both priming and amplification effects. This multi-functionality reduces the number of separate agents needed
Data Source
AI summary
The present invention relates to a kit-of-parts comprising and a composition comprising a polyplex comprising a double stranded RNA (dsRNA) and a polymeric conjugate comprising a polyethyleneimine (PEI), one or more polyethylene glycol (PEG) moieties and one or more targeting moieties, and wherein each of said one or more targeting moieties is capable of 5 binding to PSMA; and at least one least one immune checkpoint modulator, wherein said at least one least one immune checkpoint modulator is capable of modulating an immune checkpoint protein. Further the invention relates to this composition or kit-of-parts for use in the treatment of cancer.